全文获取类型
收费全文 | 577篇 |
免费 | 30篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 15篇 |
妇产科学 | 5篇 |
基础医学 | 66篇 |
口腔科学 | 5篇 |
临床医学 | 30篇 |
内科学 | 148篇 |
皮肤病学 | 19篇 |
神经病学 | 3篇 |
特种医学 | 158篇 |
外科学 | 18篇 |
综合类 | 4篇 |
预防医学 | 24篇 |
药学 | 13篇 |
中国医学 | 1篇 |
肿瘤学 | 109篇 |
出版年
2023年 | 2篇 |
2022年 | 1篇 |
2021年 | 3篇 |
2020年 | 3篇 |
2019年 | 1篇 |
2018年 | 2篇 |
2017年 | 3篇 |
2016年 | 8篇 |
2015年 | 1篇 |
2014年 | 10篇 |
2013年 | 19篇 |
2012年 | 21篇 |
2011年 | 14篇 |
2010年 | 10篇 |
2009年 | 12篇 |
2008年 | 16篇 |
2007年 | 29篇 |
2006年 | 12篇 |
2005年 | 10篇 |
2004年 | 14篇 |
2003年 | 9篇 |
2002年 | 19篇 |
2001年 | 7篇 |
2000年 | 10篇 |
1999年 | 10篇 |
1998年 | 16篇 |
1997年 | 26篇 |
1996年 | 25篇 |
1995年 | 17篇 |
1994年 | 22篇 |
1993年 | 12篇 |
1992年 | 15篇 |
1991年 | 17篇 |
1990年 | 17篇 |
1989年 | 28篇 |
1988年 | 25篇 |
1987年 | 31篇 |
1986年 | 25篇 |
1985年 | 26篇 |
1984年 | 15篇 |
1983年 | 7篇 |
1982年 | 7篇 |
1981年 | 4篇 |
1980年 | 6篇 |
1979年 | 6篇 |
1978年 | 4篇 |
1977年 | 8篇 |
1976年 | 4篇 |
1975年 | 7篇 |
1974年 | 2篇 |
排序方式: 共有619条查询结果,搜索用时 15 毫秒
11.
Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. 总被引:6,自引:0,他引:6
Christine P Hans Dennis D Weisenburger Timothy C Greiner Wing C Chan Patricia Aoun Gregory T Cochran Zenggang Pan Lynette M Smith James C Lynch Robert Gregory Bociek Philip J Bierman Julie M Vose James O Armitage 《Modern pathology》2005,18(10):1377-1384
We sought to determine whether identification of poor-risk subgroups of diffuse large B-cell lymphoma (DLBCL) using immunohistochemical stains would have practical utility with regard to prognosis and therapeutic decisions. Tissue microarray blocks were created using replicate samples of formalin-fixed, paraffin-embedded tissue from 200 cases of de novo DLBCL. The sections were stained with antibodies to proteins that are expressed by activated or proliferating B cells including MUM1, FOXP1, bcl-2, survivin, protein kinase C-beta (PKC-beta), cyclin D2, cyclin D3, and Ki-67. In univariate analysis, tumor expression of cyclin D2 (P = 0.025) or PKC-beta (P = 0.015) was associated with a worse overall survival, whereas none of the other markers was predictive of overall survival. Patients with DLBCL that expressed either cyclin D2 or PKC-beta had a 5-year overall survival of only 30% as compared to 52% for those who were negative for both markers (P = 0.0019). In multivariate analysis, the expression of cyclin D2 or PKC-beta was an independent predictor of poor overall survival (P = 0.035). Cyclin D2 and PKC-beta expression will be useful in designing a 'biological prognostic index' for patients with DLBCL. 相似文献
12.
13.
Congenital pulmonary atresia with ventricular septal defect: angiographic and surgical correlates 总被引:1,自引:0,他引:1
Of 181 patients with severe congenital pulmonary atresia and ventricular septal defect or "type IV truncus" (an obsolete term), all but 11% had true central pulmonary arteries. These arteries were demonstrable by large serial biplane angiograms using multiple selective injections into collateral vessels, frequent photographic subtraction, and occasional pulmonary vein-wedge angiograms. These techniques are extremely important for accurate diagnosis and in planning corrective or palliative surgery, which was done in 77% of patients with pulmonary arteries. 相似文献
14.
15.
Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia 总被引:4,自引:0,他引:4
Pavletic ZS Arrowsmith ER Bierman PJ Goodman SA Vose JM Tarantolo SR Stein RS Bociek G Greer JP Wu CD Kollath JP Weisenburger DD Kessinger A Wolff SN Armitage JO Bishop MR 《Bone marrow transplantation》2000,25(7):717-722
The objective of this study was to describe the outcome of allogeneic stem cell transplantation (alloSCT) in a series of patients with B cell chronic lymphocytic leukemia (B-CLL). Twenty-three B-CLL patients were transplanted between 1988 and 1997 using stem cells from a related (n = 20) or an unrelated donor (n = 3). The median age of the patients was 46 years, and the median number of prior chemotherapy regimens received was two. At transplantation, 14 patients had chemorefractory disease and 12 of these were refractory to fludarabine. The preparative regimens included total body irradiation (TBI) in 22 of the 23 cases. All patients received graft-versus-host disease (GVHD) prophylaxis with cyclosporine and methotrexate. Twenty patients (87%) achieved a complete remission (CR). The incidence of grade II-IV acute GVHD was 54%. Fourteen (61%) patients are alive and disease-free, including two with unrelated donors, at a median of 26 months (range, 9-115 months). Nine patients (39%) have died, one of whom had progressive B-CLL. The only favorable prognostic factor for failure-free survival (FFS) and overall survival (OS) after alloSCT was the use of a cyclophosphamide/TBI rather than an etoposide/cyclophosphamide/TBI regimen (P = 0.03). The projected 5-year FFS, OS, and relapse rates after alloSCT were 65% (95% CI, 48-88%), 62% (95% CI, 43-88%), and 5% (95%, CI 0-13%), respectively. These findings demonstrate the potential of high-dose therapy and alloSCT for inducing and maintaining a remission in patients with advanced or chemorefractory B-CLL. The low relapse rate may be due to an allogeneic graft-versus-leukemia effect. 相似文献
16.
Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease. 总被引:2,自引:0,他引:2
J O Armitage P J Bierman J M Vose J R Anderson D D Weisenburger A Kessinger E C Reed W P Vaughan P F Coccia D T Purtilo 《The American journal of medicine》1991,91(6):605-611
PURPOSE: High-dose therapy and autologous bone marrow transplantation (ABMT) are being increasingly utilized for the management of patients with relapsed Hodgkin's disease. Because patients with relapsed Hodgkin's disease often initially respond to salvage chemotherapy regimens, ABMT is frequently delayed until late in the course of the disease. The optimal timing for ABMT has not been identified. The purpose of this study was to determine the value of ABMT earlier in the course of Hodgkin's disease. PATIENTS AND METHODS: We treated 70 patients between October 1984 and October 1988 with high-dose cyclophosphamide, carmustine, and etoposide, followed by infusion of previously cryopreserved autologous bone marrow, and analyzed the results to determine the impact of timing of ABMT on treatment outcome. One (17 patients), two (24 patients), or three or more (29 patients) chemotherapy regimens had failed in patients before ABMT. RESULTS: The results for all 70 patients included a complete remission rate of 59%, an early death rate of 11%, a 4-year survival of 47%, and 27% of all treated patients alive and in complete remission at 4 years. The median follow-up for patients remaining in complete remission is 56 months (range 26 to 73 months). The frequency of achieving a complete remission was higher in patients in whom fewer regimens had failed before ABMT (i.e., 82% versus 58% versus 45%, p = 0.02), as was the 4-year disease-free survival (i.e., 44% versus 33% versus 21%, p = 0.04). CONCLUSION: ABMT is a more effective therapy when used early for patients with relapsed Hodgkin's disease. 相似文献
17.
18.
Samantha L. Kendrick Lucas Redd Andrea Muranyi Leigh A. Henricksen Stacey Stanislaw Lynette M. Smith Anamarija M. Perry Kai Fu Dennis D. Weisenburger Andreas Rosenwald German Ott Randy D. Gascoyne Elaine S. Jaffe Elías Campo Jan Delabie Rita M. Braziel James R. Cook Raymond R. Tubbs Louis M. Staudt Wing Chung Chan Christian Steidl Thomas M. Grogan Lisa M. Rimsza 《Human pathology》2014
19.
Muringampurath-John D Jaye DL Flowers CR Saxe D Chen Z Lechowicz MJ Weisenburger DD Bast M Arellano ML Bernal-Mizrachi L Heffner LT McLemore M Kaufman JL Winton EF Lonial S Armitage JO Khoury HJ 《British journal of haematology》2012,158(5):608-614
Diffuse large B‐cell lymphoma (DLBCL) occasionally presents with circulating malignant cells. The clinical characteristics and long‐term outcomes of these patients have not been described. Twenty‐nine newly diagnosed DLBCL presenting in leukaemic phase were identified between 1996 and 2010, at two institutions. Median age was 48 years, and patients presented with leucocytosis, high lactate dehydrogenase levels, B symptoms, and high International Prognostic Index score. Extra nodal site involvement was observed in all patients and affected the bone marrow (100%), spleen (62%), pleura/lung (41%), liver (21%), bone (17%), bowels (7%) and cerebrospinal fluid (14%). Blood lymphomatous cells co‐expressed CD19, CD20, CD22, CD38, CD45, HLA‐DR and FMC7 in >90%, and kappa or lambda light chain restriction in >50%. Ninety per cent received rituximab and anthracycline‐based chemotherapy. Overall, remission was complete in 54% and partial in 31%; 15% had resistant disease. Median follow‐up was 47 months; 13 (45%) patients remain alive in complete remission. Median progression‐free and overall survivals were 11·5 and 46·7 months, respectively. In summary, patients with DLBCL in leukaemic phase present with high tumour burden and frequent involvement of extra nodal sites. In this uncommon DLBCL subgroup, anthracycline‐based regimens with rituximab are associated with early morbidity and mortality, but yield approximately 50% 4‐year survival. 相似文献
20.
von Willebrand factor released from Weibel-Palade bodies binds more avidly to extracellular matrix than that secreted constitutively 总被引:8,自引:5,他引:8
Large multimers of von Willebrand factor (vWf) are released from the Weibel-Palade bodies of cultured endothelial cells following treatment with a secretagogue (Sporn et al, Cell 46:185, 1986). These multimers were shown by immunofluorescent staining to bind more extensively to the extracellular matrix of human foreskin fibroblasts than constitutively secreted vWf, which is composed predominantly of dimeric molecules. Increased binding of A23187-released vWf was not due to another component present in the releasate, since releasate from which vWf was adsorbed, when added together with constitutively secreted vWf, did not promote binding. When iodinated plasma vWf was overlaid onto the fibroblasts, the large forms bound preferentially to the matrix. These results indicated that the enhanced binding of the vWf released from the Weibel-Palade bodies was likely due to its large multimeric size. It appears that multivalency is an important component of vWf interaction with the extracellular matrix, just as has been shown for vWf interaction with platelets. The pool of vWf contained within the Weibel-Palade bodies, therefore, is not only especially suited for platelet binding, but also for interaction with the extracellular matrix. 相似文献